Tony Berberabe, MPH

Investigators of a phase 1a trial report high objective response rates in patients receiving forimtamig for relapsed/refractory multiple myeloma, including those with high-risk cytogenetics and extra medullary disease.

It may be an optimal approach to improve first-line treatment options to prevent relapse in those with T-cell acute lymphoblastic leukemia, according to Kristen O’Dwyer, MD.

Most adverse effects in a phase 2 trial related to doxorubicin appear to be expected in the treatment of patients with soft tissue sarcoma.

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.

Findings from the phase 3 SUNLIGHT study highlight favorable overall survival and disease control rates with the use of bevacizumab plus trifluridine and tipiracil in metastatic colorectal cancer.

Findings from the final analysis phase 3 SINTRA-REV trial indicated that lenalidomide lowered the risk of transfusion dependency when administered at a low dose in patients with myelodysplastic syndrome.

ARV-471 monetherapy showed clinical benefit in an expansion cohort of patients with locally advanced or metastatic breast cancer, according to data from the VERITAC trial.

Investigators believe that disease modifying agents may demonstrate benefit in patients with myeloproliferative neoplasms prior to allogeneic hematopoietic cell transplant.

Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.

Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.

Data on next line of therapy from the phase 3 Study 309/KEYNOTE-775 trial emphasized the benefit of lenvatinib plus pembrolizumab for advanced endometrial cancer.

High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk diffuse large B-cell lymphoma.

Patients with upper tract urothelial carcinoma may benefit from treatment with oral FGFR1-3 inhibitor infigratinib.

The use of axicabtagene ciloleucel for relapse/refractory indolent non-Hodgkin lymphoma continued the duration of response during the follow-up of the phase 2 ZUMA-5 trial.

The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.

Treatment with cabozantinib in the second line yielded responses in patients with advanced renal cell carcinoma who received immunotherapy in the frontline, regardless of prior regimen.

Patients with previously treated metastatic urothelial carcinoma or renal cell carcinoma experienced promising benefit from treatment with niraparib and cabozantinib.

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.

Using the International Prognostic Scoring System (IPSS) score and JAK2 mutation status, thrombosis risk could potentially be identified for patients with primary myelofibrosis.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by transplant continues to show superior efficacy vs triplet therapy alone at a 2-year follow-up to the GRIFFIN trial.

Patients with newly diagnosed, transplant-eligible multiple myeloma continue to experience robust and durable responses to treatment with daratumumab, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant followed by daratumumab plus lenalidomide maintenance.

Patients with HER2-positive breast cancer appeared to derive a higher overall survival benefit after being treated with pyrotinib plus capecitabine vs lapatinib plus capecitabine.

Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.

Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.

Patients with high-risk polycythemia vera had a worse survival probability at 4 years compared to patients with low-risk disease.

Further results from the KEYNOTE-426 trial continue to support the combination of pembrolizumab plus axitinib in patients with clear cell renal cell carcinoma.

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.

Results from the phase 3 KEYNOTE-811 study indicated that pembrolizumab and trastuzumab plus chemotherapy yielded robust, long-lasting responses in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.